Title : The value of blood biomarkers of progression and prognosis in ALK-positive patients with non-small cell lung cancer treated with crizotinib.

Pub. Date : 2020 Feb

PMID : 31721468






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The value of blood biomarkers of progression and prognosis in ALK-positive patients with non-small cell lung cancer treated with crizotinib. crizotinib ALK receptor tyrosine kinase Homo sapiens
2 METHODS: This is a retrospective single-center study and enrolled 113 staged IIIB-IV ALK-positive NSCLC patients who had received crizotinib treatment. crizotinib ALK receptor tyrosine kinase Homo sapiens
3 CONCLUSIONS: Trend of NLR, dNLR, PLR and WBC could be used to identify patients progress status in ALK-positive NSCLC patients receiving crizotinib. crizotinib ALK receptor tyrosine kinase Homo sapiens